5'UTR +24T>C CR2 is not associated with Nasopharyngeal Carcinoma development in the North Region of Portugal. - PubMed - NCBI
Oral Dis. 2016 Jan 9. doi: 10.1111/odi.12436. [Epub ahead of print]
5'UTR +24T>C CR2 is not associated with Nasopharyngeal Carcinoma development in the North Region of Portugal.
Sousa H1,2,
Bastos MJ1,
Ribeiro J1,
Oliveira S1,
Breda E3,
Catarino R1,
Medeiros R1,2,4,5,6.
Abstract
OBJECTIVE:
We have analysed the association of the +24T>C polymorphism (rs3813946) in CR2, the cellular receptor for Epstein-Barr Virus (EBV), in the susceptibility for the development of Nasopharyngeal Carcinoma (NPC). METHODS:
A retrospective case-control study was developed with peripheral blood samples from 111 individuals with NPC and 608 healthy individuals (controls) from the North region of Portugal. The genotyping analysis was performed by Allelic Discrimination Real-Time PCR using a TaqMan® SNP Genotyping Assay. RESULTS:
The genotype distribution was 62.2% TT, 34.2% TC and 3.6% CC for NPC patients; and 65.0%, 30.6% and 4.4%, respectively, for controls. Our study showed no statistical association between the genotypes distribution in controls and all types of NPC (p=0.717), nevertheless the analysis showed statistically significant differences (p=0.038) regarding cases with well or moderated differentiated types of NPC suggesting that +24CC/CT genotypes are associated with increased risk (OR=4.16; 95%CI 1.28-15.7; p=0.016). CONCLUSIONS:
This is the first study in western populations to characterize the association of the CR2 +24T>C polymorphism in NPC development and our results suggest that more studies are required to clarify the impact on NPC susceptibility in different populations. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
KEYWORDS:
CR2/CD21; Cancer; Nasopharyngeal Carcinoma; polymorphism
- PMID:
- 26748973
- [PubMed - as supplied by publisher]
No hay comentarios:
Publicar un comentario